AnnouncementsNATCO comments on Copaxone patent
100% of moneycontrol users recommend holding Natco Pharma.
What's your call on Natco Pharma today?
Read 23 investor views
|Company Name||Last Price||%
|Dr Reddys Labs||2565.45||0.50||2939.80||1999.40||43,640.58|
|Dec' 13||Sep' 13||Jun' 13||Mar' 13|
|Scheme||No. of Shares|
|ICICI Prudential Discovery Fund (G)||857,116|
|SBI Magnum Tax Gain Scheme (G)||355,881|
|SBI Magnum Multiplier Plus (G)||228,949|
|ICICI Prudential Exports and Other Services Fund (G)||148,511|
Natco Pharma is in the Pharmaceuticals sector. The current market capitalisation stands at Rs 2,806.62 crore.The company has reported a consolidated sales of Rs 186.18 crore and a Net Profit of Rs 27.45 crore for the quarter ended Dec 2013.
The company management includes V C Nannapaneni - Chairman & Managing Director, Rajeev Nannapaneni - Vice Chairman & CEO, T V Rao - Nominee Director, G S Murthy - Director, B S Bajaj - Director, P Bhaskara Narayana - Director & CFO, A K S Bhujanga Rao - President & Director, Vivek Chhacchi - Additional Director, D G Prasad - Additional Director.
It is listed on the BSE with a BSE Code of 524816 and the NSE with an NSE Code of NATCOPHARM.
Its Registered office is at NATCO House, Road No.2,,Banjara Hills Hyderabad,Andhra Pradesh - 500034.
Their Registrars are Venture Capital & Corporate Investments Pvt. Ltd.